The Life Sciences team advised ImmuNext Inc. on its option and license agreement with Curis, Inc. (NASDAQ: CRIS). Under the agreement, Curis has an option to obtain an exclusive, worldwide license from ImmuNext to develop and commercialize anti-VISTA antibodies for the treatment of cancer, including ImmuNext's lead compound, CI-8993, a clinical-stage monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (VISTA) signaling pathway.
ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases. ImmuNext currently has a clinical stage program with VISTA, a checkpoint regulator, and pre-clinical programs focused on the development of antibodies that target novel immuno-metabolic proteins. Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer.
The Goodwin team was led by Kathleen Kean, Sarah Solomon and Sarah Stoiber.
For more details, read the press release.